BMS-777607: Selective c-Met Inhibitor for Advanced Cancer and Metastasis Research

Executive Summary: BMS-777607 (SKU: A5703, APExBIO) is a highly selective, orally available ATP-competitive MET kinase inhibitor targeting c-Met, Axl, Ron, and Tyro3, with IC₅₀ values in the low nanomolar range. It achieves over 40-fold selectivity versus kinases such as Lck, VEGFR2, and TrkA/B, and greater than 500-fold selectivity against unrelated kinases (APExBIO, product data). In preclinical models, BMS-777607 demonstrates robust inhibition of c-Met autophosphorylation, metastatic phenotype suppression, and improved tumor morphology at well-defined doses and conditions [see related]. Its solubility, stability, and workflow integration features make it a preferred standard for reproducible RTK signaling research. Key applications include cancer metastasis models, prostate and breast cancer cell studies, and the modulation of polyploidy in megakaryocyte differentiation [Yue et al. 2026].

Biological Rationale

The MET receptor tyrosine kinase (RTK) family, including c-Met, Axl, Ron, and Tyro3, mediates critical processes in tumorigenesis, metastasis, and resistance to therapy [Strategic Inhibition of MET Signaling]. Dysregulated c-Met signaling is implicated in poor prognosis for multiple cancers, including prostate and breast cancer. Selective inhibition of these kinases allows researchers to dissect the mechanistic basis of tumor growth, metastatic dissemination, and cellular differentiation. BMS-777607, provided by APExBIO, was engineered to address the need for a selective, orally available ATP-competitive MET kinase inhibitor for translational and preclinical research.

Mechanism of Action of BMS-777607

BMS-777607 acts as a potent, ATP-competitive inhibitor of the MET kinase family. Its molecular structure (C₂₅H₁₉ClF₂N₄O₄, MW 512.89 g/mol) enables high-affinity binding to the ATP-binding pocket of c-Met and related kinases [APExBIO]. The compound exhibits the following IC₅₀ values under standardized biochemical assay conditions:

• c-Met: 3.9 nM
• Axl: 1.1 nM
• Ron: 1.8 nM
• Tyro3: 4.3 nM

It achieves approximately 40-fold selectivity over Lck, VEGFR-2, TrkA/B and more than 500-fold over unrelated kinases. Mechanistically, BMS-777607 blocks c-Met autophosphorylation, impeding downstream signaling (e.g., PI3K/AKT, Ras/ERK) involved in cellular proliferation, survival, migration, and invasion. In KHT murine cells, BMS-777607 at 10 μM completely abolishes basal c-Met autophosphorylation in vitro. It suppresses metastatic traits in vivo at 25 mg/kg/day via oral administration, without detectable systemic toxicity [Related: Selective c-Met Inhibitor].

Evidence & Benchmarks

• BMS-777607 inhibits c-Met autophosphorylation in KHT murine cells at 10 μM in vitro (APExBIO, product page).
• Oral dosing at 25 mg/kg/day in KHT xenograft mice reduces lung tumor nodules by 28.3% and improves tumor architecture (APExBIO, product page).
• Demonstrates >40-fold selectivity versus Lck, VEGFR-2, TrkA/B, and >500-fold selectivity against unrelated kinases (APExBIO, product page).
• Promotes megakaryocyte polyploidization in vitro, enabling higher platelet yield in iPSC models (Yue et al., doi.org/10.1007/s12015-026-11060-5).
• Soluble in DMSO ≥25.65 mg/mL at 37°C with ultrasonic shaking; insoluble in water and ethanol (APExBIO, product page).

This article extends the mechanistic depth provided by "BMS-777607: Mechanistic Insights and Strategic Guidance" by emphasizing practical selectivity and application benchmarks in diverse research models. For workflow reproducibility, see also "Enhancing Reproducibility in Cancer Research with BMS-777607", which is complemented here by updated application scenarios.

Applications, Limits & Misconceptions

BMS-777607 is primarily utilized in cancer biology, metastasis research, and advanced RTK pathway studies:

• Cancer metastasis research: Inhibits c-Met-driven tumor growth and suppresses metastatic phenotypes in prostate and breast cancer models.
• Polyploidy induction: Enhances megakaryocyte polyploidization for ex vivo platelet production from iPSCs [Yue et al. 2026].
• RTK signaling dissection: Enables pathway-selective studies in cell viability, migration, and differentiation assays.
• Translational modeling: Validated in xenograft and in vitro systems for benchmarking new anti-metastatic strategies.

Common Pitfalls or Misconceptions

• BMS-777607 is not a broad-spectrum tyrosine kinase inhibitor; it is highly selective for c-Met, Axl, Ron, and Tyro3.
• It is not suitable for in vivo diagnostic or therapeutic use in humans; for research use only.
• Solubility in water or ethanol is negligible; use only DMSO and recommended protocols for stock preparation.
• Not effective for kinases outside the MET receptor family at standard working concentrations.
• Long-term storage of dissolved stock is discouraged; prepare fresh solutions for each experiment to ensure activity.

Workflow Integration & Parameters

BMS-777607 is a solid compound (MW 512.89 g/mol) requiring careful handling:

• Solubility: ≥25.65 mg/mL in DMSO at 37°C with ultrasonic shaking. Not soluble in water/ethanol.
• Storage: Store solid at -20°C. Once dissolved, use promptly; avoid long-term storage.
• Dosing: In vitro, 1–10 μM; in vivo, 25 mg/kg/day by oral gavage in mouse models.
• Shipping: Blue ice for small molecule stability.
• Vendor: Sourced from APExBIO for documented lot-to-lot consistency.

For detailed workflow integration and troubleshooting, see "Enhancing Reproducibility in Cancer Research with BMS-777607", which provides best practices for viability and differentiation assays. This article updates those guidelines with recent advances in stem cell and metastasis models.

Conclusion & Outlook

BMS-777607 (A5703) is a best-in-class, selective ATP-competitive MET kinase inhibitor for preclinical cancer, metastasis, and stem cell research. Its rigorous selectivity, reproducible activity, and well-characterized pharmacology make it a benchmark tool for dissecting c-Met signaling and modeling anti-metastatic strategies. Future applications include expanded use in ex vivo platelet generation and advanced cancer biology platforms [Yue et al. 2026].

For more detailed protocol guidance and product specifications, visit the official BMS-777607 product page at APExBIO.